Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zoliflodacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 23,569Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innoviva's Zoliflodacin Gonorrhea Phase 3 Data at ESCMID
    Innoviva's Zoliflodacin Gonorrhea Phase 3 Data at ESCMID

    24 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240424323555/en

    BUSINESSWIRE
    24 Apr 2024
    Share Share
    Entasis Therapeutics and the Global Antibiotic Research & Development Partnership
    Entasis Therapeutics and the Global Antibiotic Research & Development Partnership

    22 Nov 2018

    // PRESS RELEASE

    https://www.dndi.org/2017/media-centre/press-releases/entasis-therapeutics-and-gardp-to-develop-new-treatment-for-drug-resistant-gonorrhea/

    PRESS RELEASE
    22 Nov 2018
    Share Share
    Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in NEJM
    Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in NEJM

    07 Nov 2018

    // GLOBENEWSWIRE

    https://globenewswire.com/news-release/2018/11/07/1647517/0/en/Entasis-Therapeutics-Announces-Zoliflodacin-Phase-2-Results-Published-in-The-New-England-Journal-of-Medicine.html

    GLOBENEWSWIRE
    07 Nov 2018
    Share Share
    AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3
    AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3

    20 Aug 2018

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/astrazeneca-spinout-entasis-files-for-86m-ipo-to-fund-antibiotic-phase-3

    Nick Paul Taylor FIERCE BIOTECH
    20 Aug 2018
    Share Share